Modern Management of Localized Renal Cell Carcinoma— Is Ablation Part of the Equation?

Leopold, Zev; Passarelli, Rachel; Mikhail, Mark; Tabakin, Alexandra L.; Chua, Kevin; Ennis, Ronald D.; Nosher, John; Singer, Eric A.

doi:10.15586/jkcvhl.v9i3.233

Cited by 5 publications

(2 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other local therapies. percutaneous ablation offers a reasonable alternative to surgery and can be performed with cryoablation or radiofrequency ablation [31]. A biopsy should confirm malignancy before ablation.…”

Section: Primary Localized Rccmentioning

confidence: 99%

Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma

Raj,

Upadhyay,

Wang

et al. 2023

Current Oncology

Self Cite

View full text Add to dashboard Cite

Stereotactic ablative radiotherapy (SABR) has challenged the conventional wisdom surrounding the radioresistance of renal cell carcinoma (RCC). In the past decade, there has been a significant accumulation of clinical data to support the safety and efficacy of SABR in RCC. Herein, we review the use of SABR across the spectrum of RCC. We performed an online search of the Pubmed database from January 1990 through April 2023. Studies of SABR/stereotactic radiosurgery targeting primary, extracranial, and intracranial metastatic RCC were included. For SABR in non-metastatic RCC, this includes its use in small renal masses, larger renal masses, and inferior vena cava tumor thrombi. In the metastatic setting, SABR can be used at diagnosis, for oligometastatic and oligoprogressive disease, and for symptomatic reasons. Notably, SABR can be used for both the primary renal tumor and metastasis-directed therapy. Management of RCC is evolving rapidly, and the role that SABR will have in this landscape is being assessed in a number of ongoing prospective clinical trials. The objective of this narrative review is to summarize the evidence corroborating the use of SABR in RCC.

show abstract

Section: Primary Localized Rccmentioning

confidence: 99%

Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma

Raj,

Upadhyay,

Wang

et al. 2023

Current Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Older, inactive people with poor eating habits are more vulnerable to cancer than younger ones. Factors that can play a vital role in cancer prevention are the least exposure to sunlight, proper vaccination of viral infections, avoiding air pollution, eating fresh vegetables and fruits, and doing some physical activity daily (Cao et al., 2022 ; Leopold et al., 2022 ; Mitsogiannis et al., 2022 ). The risk of cancer can be reduced through timely diagnosis; early cancer treatment can increase the chances of survival (Ferlay et al., 2021 ) and appropriate patient care.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic potential of mangiferin in cancer: Unveiling regulatory pathways, mechanisms of action, and bioavailability enhancements – An updated review

Iqbal,

Inam‐Ur‐Raheem,

Munir

et al. 2023

Food Science & Nutrition

View full text Add to dashboard Cite

Mangiferin (MGF) is a phenolic compound, which is a major source of MGF is the mango tree. MGF possesses some antioxidant, anti‐inflammatory, and cytoprotective properties, enabling it to play its role against various diseases such as diabetes, obesity, lung injuries, and cancer. The word “Cancer” depicts an uncontrolled and abnormal growth of cells. This review paper reveals MGF's therapeutic, curative and protective potential impact against lung, liver, ovarian, prostate, breast, stomach, and oral cancers. MGF is used in various types of research in the form of powder, liquid extract, intramuscular, intravenous, nanoparticles coated with gold, in the form of a solution, or in combination with other drugs to evaluate synergistic effects. Many studies showed that MGF is safe to use but has less bioavailability in the body and 0.111 mg/mL solubility in water. However, certain studies indicated that its bioavailability and retention time increased when taken in the form of nanoparticles and in combination with other drugs. MGF also increases the sensitivity of other drugs (i.e., cisplatin) resistant to tumors. MGF has different mechanisms of action for different cancers. It mainly targets enzymes, interleukins, tumor growth factors, signaling pathways, apoptotic proteins, and genes to inhibit the growth of tumors, volume, angiogenesis, cellular functionality, further progression, and movement to other areas of the body. Moreover, MGF increases apoptosis and body weight with no or fewer side effects on normal cells. MGF unveiled a novel gate toward the treatment of cancer. Further research and human trials are needed in this regard.

show abstract

Protection from injury to organs adjacent to a renal tumor during Imaging-guided thermal ablation with hydrodissection and pyeloperfusion

Adebanjo,

Bertolotti,

Iemma

et al. 2024

European Journal of Radiology

View full text Add to dashboard Cite

Modern Management of Localized Renal Cell Carcinoma— Is Ablation Part of the Equation?

Cited by 5 publications

References 67 publications

Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma

Incorporating Stereotactic Ablative Radiotherapy into the Multidisciplinary Management of Renal Cell Carcinoma

Therapeutic potential of mangiferin in cancer: Unveiling regulatory pathways, mechanisms of action, and bioavailability enhancements – An updated review

Protection from injury to organs adjacent to a renal tumor during Imaging-guided thermal ablation with hydrodissection and pyeloperfusion

Contact Info

Product

Resources

About